Gear Up for Phreesia (PHR) Q1 Earnings: Wall Street Estimates for Key Metrics

26.05.25 15:15 Uhr

Werte in diesem Artikel

The upcoming report from Phreesia (PHR) is expected to reveal quarterly loss of $0.13 per share, indicating an increase of 62.9% compared to the year-ago period. Analysts forecast revenues of $114.69 million, representing an increase of 13.3% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.With that in mind, let's delve into the average projections of some Phreesia metrics that are commonly tracked and projected by analysts on Wall Street.Analysts predict that the 'Revenus- Subscription and related services' will reach $52.43 million. The estimate points to a change of +12.2% from the year-ago quarter.The consensus among analysts is that 'Revenus- Network solutions' will reach $33.40 million. The estimate indicates a year-over-year change of +21.8%.Analysts forecast 'Revenus- Payment processing fees' to reach $28.87 million. The estimate points to a change of +6.7% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Average healthcare services Clients' of 4,373. Compared to the current estimate, the company reported 4,065 in the same quarter of the previous year.Analysts' assessment points toward 'Average revenue per healthcare services client' reaching $18.65 million. The estimate is in contrast to the year-ago figure of $18.24 million.According to the collective judgment of analysts, 'Patient payment volume' should come in at $1.25 billion. The estimate is in contrast to the year-ago figure of $1.17 billion.View all Key Company Metrics for Phreesia here>>>Phreesia shares have witnessed a change of -2.8% in the past month, in contrast to the Zacks S&P 500 composite's +8.2% move. With a Zacks Rank #3 (Hold), PHR is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phreesia, Inc. (PHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Phreesia und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Phreesia

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Phreesia

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Phreesia Inc Registered Shs

Wer­bung

Analysen zu Phreesia Inc Registered Shs

DatumRatingAnalyst
23.07.2019Phreesia BuyChardan Capital Markets
DatumRatingAnalyst
23.07.2019Phreesia BuyChardan Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Phreesia Inc Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen